Hsu C - Search Results

1

Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model-informed Drug Development Strategy.

Zahir H, Yin O, Hsu C, Wagner AJ, Jiang J, Wang X, Greenberg J, Shuster DE, Kakkar T, LaCreta F. Zahir H, et al. Among authors: hsu c. Clin Pharmacol Drug Dev. 2023 May;12(5):475-483. doi: 10.1002/cpdd.1240. Epub 2023 Mar 21. Clin Pharmacol Drug Dev. 2023. PMID: 36942508

2

Pharmacological modulation of peripheral T and B lymphocytes by a selective sphingosine 1-phosphate receptor-1 modulator.

Moberly JB, Rohatagi S, Zahir H, Hsu C, Noveck RJ, Truitt KE. Moberly JB, et al. Among authors: hsu c. J Clin Pharmacol. 2012 Jul;52(7):996-1006. doi: 10.1177/0091270011408728. Epub 2011 May 12. J Clin Pharmacol. 2012. PMID: 21566200 Clinical Trial.

3

Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study.

Tachibana M, Yamamura N, Atiee GJ, Hsu C, Warren V, He L, Dishy V, Zahir H. Tachibana M, et al. Among authors: hsu c. Br J Clin Pharmacol. 2018 Oct;84(10):2317-2324. doi: 10.1111/bcp.13674. Epub 2018 Aug 9. Br J Clin Pharmacol. 2018. PMID: 29920736 Free PMC article. Clinical Trial.

4

Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies.

Brown K, Mendell J, Ohwada S, Hsu C, He L, Warren V, Dishy V, Zahir H. Brown K, et al. Among authors: hsu c. Pharmacol Res Perspect. 2018 Aug 23;6(5):e00418. doi: 10.1002/prp2.418. eCollection 2018 Oct. Pharmacol Res Perspect. 2018. PMID: 30151212 Free PMC article. Clinical Trial.

5

Effect of Mild and Moderate Hepatic Impairment (Defined by Child-Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics.

Zahir H, Greenberg J, Hsu C, Marbury TC, Lasseter KC, Xu LA, Tap WD, Healey JH, Stacchiotti S, LaCreta F. Zahir H, et al. Among authors: hsu c. J Clin Pharmacol. 2022 Aug;62(8):992-1005. doi: 10.1002/jcph.2042. Epub 2022 Mar 31. J Clin Pharmacol. 2022. PMID: 35247274 Free PMC article.

6

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.

Zahir H, Greenberg J, Shuster D, Hsu C, Watanabe K, LaCreta F. Zahir H, et al. Among authors: hsu c. Clin Pharmacokinet. 2022 Nov;61(11):1623-1639. doi: 10.1007/s40262-022-01172-9. Epub 2022 Oct 20. Clin Pharmacokinet. 2022. PMID: 36264536 Free PMC article. Clinical Trial.

7

Pharmacokinetics of the Multi-kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality.

Zahir H, Greenberg J, Hsu C, Watanabe K, Makino C, He L, LaCreta F. Zahir H, et al. Among authors: hsu c. Clin Pharmacol Drug Dev. 2023 Feb;12(2):159-167. doi: 10.1002/cpdd.1186. Epub 2022 Nov 11. Clin Pharmacol Drug Dev. 2023. PMID: 36369799 Free PMC article.

8

Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study.

Arnold LM, Whitaker S, Hsu C, Jacobs D, Merante D. Arnold LM, et al. Among authors: hsu c. Curr Med Res Opin. 2019 Oct;35(10):1825-1835. doi: 10.1080/03007995.2019.1629757. Epub 2019 Jul 9. Curr Med Res Opin. 2019. PMID: 31284771 Clinical Trial.

9

Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer.

Garrido C, Manoogian M, Ghambire D, Lucas S, Karnoub M, Olson MT, Hicks DG, Tozbikian G, Prat A, Ueno NT, Modi S, Feng W, Pugh J, Hsu C, Tsurutani J, Cameron D, Harbeck N, Fang Q, Khambata-Ford S, Liu X, Inge LJ, Vitazka P. Garrido C, et al. Among authors: hsu c. Virchows Arch. 2023 Oct 20. doi: 10.1007/s00428-023-03671-x. Online ahead of print. Virchows Arch. 2023. PMID: 37857998

10

An Assessment of Clinically Important Differences on the Worst Pain Severity Item of the Modified Brief Pain Inventory in Patients with Diabetic Peripheral Neuropathic Pain.

Marcus J, Lasch K, Wan Y, Yang M, Hsu C, Merante D. Marcus J, et al. Among authors: hsu c. Pain Res Manag. 2018 Jul 22;2018:2140420. doi: 10.1155/2018/2140420. eCollection 2018. Pain Res Manag. 2018. PMID: 30140328 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14,025 results

Search Page